Concepedia

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

Joshua Haznedar, Shem Patyna, Carlo L. Bello, Geoffrey W. Peng, William C. Speed, Xiaoming Yu, Qingling Zhang, Juthamas Sukbuntherng, David J. Sweeny, Lida Antonian

Cancer Chemotherapy and Pharmacology · 2009 · 64 citations · 13 references

DOI

Concepts

References

13

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

, , +15

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen et al. · Blood · 2003 · 857 citations · Full text

, , +11

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Tinya J. Abrams, Leslie B. Lee, Lesley Murray et al. · PubMed · 2003 · 639 citations

, , +17

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Harold J. Burstein, Anthony Elias, Hope S. Rugo et al. · Journal of Clinical Oncology · 2008 · 484 citations · Full text

, , +17

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

Mark A. Socinski, Silvia Novello, Julie R. Brahmer et al. · Journal of Clinical Oncology · 2008 · 321 citations · Full text

, , +17